Meeting
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
Authors
Frederick L. Locke
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Frederick L. Locke , Lazaros J. Lekakis , Herbert Eradat , Javier Munoz , Michael Timothy Tees , Sven de Vos , Rajneesh Nath , Don A. Stevens , Shahbaz Malik , Leslie Popplewell , Mehdi Hamadani , Olalekan O. Oluwole , Miguel-Angel Perales , David Bernard Miklos , Paul Fisher , Lovely Goyal , Gregory Kaufman , Kazuharu Kai , Arun Balakumaran , Sattva Swarup Neelapu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03939026
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2517)
DOI
10.1200/JCO.2023.41.16_suppl.2517
Abstract #
2517
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
First Author: Loretta J. Nastoupil
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto